Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
Fhd-609
Advanced Synovial Sarcoma
Phase I
Terminated
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Jun 26, 2021
―
Decitabine, Fhd-286, Low Dose Cytarabine
Refractory Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia, Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
Phase I
Active Not Recruiting
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
May 13, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Foghorn Therapeutics (FHTX) have in its pipeline
FHTX is currently developing the following drugs: Fhd-609, Decitabine, Fhd-286, Low Dose Cytarabine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.